ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
简
繁
EN
INVESTEE NEWS
MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
2019.05.14
Download
Related news
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
2019-07-22
MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
2019-05-14
Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies
2019-02-28